Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer

[1]  L. Esserman,et al.  Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. , 2022, JAMA surgery.

[2]  Frederick M. Howard,et al.  Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform , 2022, Breast Cancer Research and Treatment.

[3]  J. Weis,et al.  Dynamic characterization of breast cancer response to neoadjuvant therapy using biophysical metrics of spatial proliferation , 2022, Scientific Reports.

[4]  S. Schnitt,et al.  Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer , 2022, Annals of Surgical Oncology.

[5]  Bowen Zheng,et al.  Spatially resolved transcriptomics provide a new method for cancer research , 2022, Journal of experimental & clinical cancer research : CR.

[6]  G. Sala,et al.  Breast cancer in the era of integrating “Omics” approaches , 2022, Oncogenesis.

[7]  Joseph R. Peterson,et al.  Abstract P1-08-31: Simbiosys tumorscope: Biophysical modeling of patient-specific response to chemotherapy , 2022, Cancer Research.

[8]  Frederick M. Howard,et al.  Abstract P4-05-03: Evaluation of the prognostic accuracy of SimBioSys TumorScope in early breast cancer , 2022, Cancer Research.

[9]  Gabor T. Marth,et al.  A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology , 2022, Nature Cancer.

[10]  R. Gelber,et al.  Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis , 2021, BMJ.

[11]  L. Esserman,et al.  Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients , 2021, The Lancet. Oncology.

[12]  David A. Ekrut,et al.  Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting , 2021, Nature Protocols.

[13]  Eun Sook Ko,et al.  Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer , 2021, Scientific Reports.

[14]  K. Hoyt,et al.  Multiscale computational modeling of cancer growth using features derived from microCT images , 2021, Scientific Reports.

[15]  E. Jaffee,et al.  Forecasting cancer: from precision to predictive medicine. , 2021, Med.

[16]  Stephen R. Williams,et al.  A single-cell and spatially resolved atlas of human breast cancers , 2021, Nature Genetics.

[17]  Brian M. Larsen,et al.  A pan-cancer organoid platform for precision medicine. , 2021, Cell reports.

[18]  K. Gourevich,et al.  Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer , 2021, American journal of clinical oncology.

[19]  J. Rosen,et al.  Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. , 2021, Seminars in cancer biology.

[20]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  T. Yankeelov,et al.  Image-based personalization of computational models for predicting response of high-grade glioma to chemoradiation , 2021, Scientific Reports.

[22]  E. Winer,et al.  Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Ricci-Cabello,et al.  Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries , 2020, BMC Health Services Research.

[24]  K. Rahbar,et al.  PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  I. Endo,et al.  Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer , 2020, International journal of molecular sciences.

[26]  G. Johnson,et al.  PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker? , 2020, Seminars in nuclear medicine.

[27]  T. Go,et al.  Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer , 2020, AntiCancer Research.

[28]  Joseph R. Peterson,et al.  Perfusion kinetics from clinical DCE mris increase the accuracy of predictions of tumor response to chemotherapy. , 2020 .

[29]  Joseph R. Peterson,et al.  SimBioSys TumorScope: Spatio-temporal modeling of the tumor microenvironment to predict chemotherapeutic response. , 2020 .

[30]  Joseph R. Peterson,et al.  Spatiotemporal modeling with SimBioSys TumorScope to predict chemotherapeutic response in breast tumor microenvironments. , 2020 .

[31]  K. Rahbar,et al.  Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer , 2020, The Journal of Nuclear Medicine.

[32]  J. Fütterer,et al.  The Effect of Higher Level Computerized Clinical Decision Support Systems on Oncology Care: A Systematic Review , 2020, Cancers.

[33]  Joseph R. Peterson,et al.  Abstract P1-06-04: SimBioSys TumorScope: Spatio-temporal modeling of the breast tumor microenvironment accurately predicts chemotherapeutic response , 2020 .

[34]  Shivajirao M. Jadhav,et al.  Deep convolutional neural network based medical image classification for disease diagnosis , 2019, Journal of Big Data.

[35]  S. Kim,et al.  Advances in Diffusion and Perfusion MRI for Quantitative Cancer Imaging , 2019, Current Pathobiology Reports.

[36]  Rhea D. Chitalia,et al.  Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence , 2019, Clinical Cancer Research.

[37]  E. Matano,et al.  Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer , 2019, Annals of Nuclear Medicine.

[38]  Laura Keller,et al.  Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells , 2019, Nature Reviews Cancer.

[39]  Michael Hinczewski,et al.  The 2019 mathematical oncology roadmap , 2019, Physical biology.

[40]  K. Kitajima,et al.  Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy , 2019, Annals of Surgical Oncology.

[41]  Kun Wang,et al.  Tumor location of the central and nipple portion is associated with impaired survival for women with breast cancer , 2019, Cancer management and research.

[42]  Chengyue Wu,et al.  Quantitative analysis of vascular properties derived from ultrafast DCE‐MRI to discriminate malignant and benign breast tumors , 2018, Magnetic resonance in medicine.

[43]  L. Kooreman,et al.  Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. , 2020, Annals of surgery.

[44]  Y. Tsushima,et al.  Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer , 2018, BMC Medical Imaging.

[45]  Maciej A. Mazurowski,et al.  Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set , 2018, Breast Cancer Research and Treatment.

[46]  J. Boughey,et al.  The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB) , 2018, Annals of surgery.

[47]  S. Bhatia,et al.  Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[48]  M. Nishino.  Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[49]  A. Thompson,et al.  Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. , 2018, The British journal of radiology.

[50]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[51]  G. Turashvili,et al.  Tumor Heterogeneity in Breast Cancer , 2017, Front. Med..

[52]  Jeong Eon Lee,et al.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.

[53]  Patrick Soon-Shiong,et al.  Molecular heterogeneity in breast cancer: State of the science and implications for patient care. , 2017, Seminars in cell & developmental biology.

[54]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[55]  S. Masood.  Neoadjuvant chemotherapy in breast cancers , 2016, Women's health.

[56]  Seyed-Ahmad Ahmadi,et al.  V-Net: Fully Convolutional Neural Networks for Volumetric Medical Image Segmentation , 2016, 2016 Fourth International Conference on 3D Vision (3DV).

[57]  F. Rojo,et al.  High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer , 2016, The oncologist.

[58]  Ash A. Alizadeh,et al.  Toward understanding and exploiting tumor heterogeneity , 2015, Nature Medicine.

[59]  J. Wildberger,et al.  The Quality of Tumor Size Assessment by Contrast-Enhanced Spectral Mammography and the Benefit of Additional Breast MRI , 2015, Journal of Cancer.

[60]  John Kornak,et al.  Optimized breast MRI functional tumor volume as a biomarker of recurrence‐free survival following neoadjuvant chemotherapy , 2014, Journal of magnetic resonance imaging : JMRI.

[61]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[62]  Thomas E Yankeelov,et al.  Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.

[63]  Quynh-Thu Le,et al.  Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. , 2012, Clinical lung cancer.

[64]  Andrew H. Beck,et al.  Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.

[65]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  F. Bertucci,et al.  Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer , 2009, Breast Cancer Research.

[68]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  L. Esserman,et al.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.

[71]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[72]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[73]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[74]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .